Big Pharma's New Weapon Against Washington Is a Former Congressman

For pharma companies with blockbuster drugs that rely heavily on Medicare revenue, every expansion of this program is a direct hit to the bottom line.

Follow the Money

If you want to understand how seriously the industry takes this threat, look at what they're spending. PhRMA dropped roughly $37.9 million on lobbying in 2025, up from about $31 million the year before. By some counts, the figure was closer to $38.2 million, with more than 40 outside lobbying firms on retainer by mid-2025.

That's not a lobbying budget. That's a war chest.

The group has been adding firepower, too, retaining new firms and building coalitions to fight on multiple fronts: Medicare negotiation, pharmacy benefit manager (PBM) reform, tariffs, and something the industry calls the "pill penalty." That's a provision in the IRA that subjects small-molecule drugs (traditional pills) to price negotiation sooner than biologics (complex, lab-grown medicines), which pharma argues discourages investment in the very drugs that are cheapest to manufacture and distribute.

The Revolving Door Spins Again

Let's be honest about what this hire represents. Cantor's appointment is the latest example of a well-worn Washington tradition: a powerful politician leaves government, spends time in the private sector, and then lands at the intersection of industry and influence.

Politico characterized the PhRMA CEO role as one of Washington's most lucrative lobbying jobs, and it's easy to see why. The group is the tip of the spear for an industry that collectively spends more on lobbying than almost any other sector in America.

PhRMA described the appointment in glowing terms, saying Cantor brings "decades of experience at the intersection of business and public policy" at a "pivotal moment" for the industry. The U.S. Chamber of Commerce congratulated him, praising his "vast experience in government and the private sector" and "deep knowledge of public policy."

Translation: he knows the people who write the laws, and he knows how to talk to them.

What Cantor Actually Has to Do

The to-do list waiting on Cantor's desk is daunting. His predecessor, Ubl, navigated PhRMA through years of escalating drug-pricing scrutiny; he was described as the group's longest-tenured CEO. But Ubl is leaving at a moment when the pressure is intensifying, not easing.

Cantor's core mandate will be to slow down, soften, or reshape the Medicare negotiation program before it swallows more products. He'll also need to keep pushing Congress to regulate PBMs (the middlemen between drug companies, insurers, and pharmacies) as an alternative villain in the drug-pricing story. And he'll have to manage the industry's relationship with an administration that has publicly promised lower drug prices while also pursuing tariff policies that complicate pharmaceutical supply chains.

It's a balancing act that requires someone who can work both sides of the aisle and both ends of Pennsylvania Avenue. Congress, HHS, and the White House are all in play simultaneously.

The Bigger Picture

PhRMA's choice tells you where the pharmaceutical industry thinks the real battlefield is. It's not in the lab. It's not at the FDA. It's in the halls of Congress and the rulemaking offices at CMS.

When a trade group representing the world's largest drugmakers decides its most important hire is a former House Majority Leader, the message is clear: the industry believes this war will be won or lost through political influence, not scientific breakthroughs.

Whether that strategy works depends on whether Cantor can convert his Rolodex into real policy wins. PhRMA's members are counting on it. Patients waiting for lower drug prices? They might have a different opinion about who should be running the show.

The Obesity Drug That Worked Better at a Lower Dose

Zealand Pharma's obesity drug petrelintide posted 9.8% weight loss in Phase 2, but with a catch: the middle dose outperformed the highest one. The inverted dose-response curve complicates Phase 3 planning and raises fascinating questions about the limits of amylin biology.